Correction: SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy
Authors: Gregory E. Edelstein, BA*, Julie Boucau, PhD*, Rockib Uddin, BS, Caitlin Marino, BS, May Y. Liew, BA
Journal: Annals of Internal Medicine (2024)

Corrections20 February 2024Correction: SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir TherapyFREEThis correction concerns the following article:Original ResearchDec 2023SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir TherapyFREEGregory E. Edelstein, BA*, Julie Boucau, PhD*, Rockib Uddin, BS, Caitlin Marino, BS, May Y. Liew, BAGregory E. Edelstein, BA*Brigham and Women's Hospital, Boston, Massachusetts (G.E.E., Y.K., J.A.S.), Julie Boucau, PhD*Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts (J.B., C.M.), Rockib Uddin, BSMassachusetts General Hospital, Boston, Massachusetts (R.U., M.Y.L., M.B., R.F.G., Z.R., D.T., S.S., T.D.V., S.P.H., Z.W.), Caitlin Marino, BSRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts (J.B., C.M.), May Y. Liew, BAMassachusetts General Hospital, Boston, Massachusetts (R.U., M.Y.L., M.B., R.F.G., Z.R., D.T., S.S., T.D.V., S.P.H., Z.W.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L24-0045 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In the article by Edelstein and colleagues (1), a reader (2) identified an error in Table 1 that was caused by rounding errors in the percentages. The authors have addressed these in the corrected version of the table.The corrections are as follows:The "Unknown/missing" characteristic for race in the "No COVID-19 Therapy (n = 55)" category has been updated from 3 (6) to 3 (5).The "Incomplete" characteristic for COVID-19 variant in the "No COVID-19 Therapy (n = 55)" category has been updated from 14 (26) to 14 (25).The "Screening" characteristic for reason for baseline test in the "Nirmatrelvir–Ritonavir (n = 72)" category has been updated from 1 (2) to 1 (1).The "Other" characteristic for reason for baseline test in the "No COVID-19 Therapy (n = 55)" category has been updated from 1 (1) to 1 (2).In addition, a percentage in the text was misreported as 81.2% instead of 81.3%.None of the errors was related to the statistical models or estimation of primary or secondary results. They do not affect any of the primary outcomes, conclusions, or implications. The table and text have been updated accordingly.References1. Edelstein GE, Boucau J, Uddin R, et al. SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy. An observational study. Ann Intern Med. 2023;176:1577-1585. [PMID: 37956428] doi:10.7326/M23-1756 LinkGoogle Scholar2. Li L. Re: SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy. An observational study. Online comment. Ann Intern Med. 15 December 2023. Accessed at www.acpjournals.org/doi/10.7326/M23-1756#_comments on 7 February 2024. Google Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationThis article was published at Annals.org on 20 February 2024. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy Gregory E. Edelstein , Julie Boucau , Rockib Uddin , Caitlin Marino , May Y. Liew , Mamadou Barry , Manish C. Choudhary , Rebecca F. Gilbert , Zahra Reynolds , Yijia Li , Dessie Tien , Shruti Sagar , Tammy D. Vyas , Yumeko Kawano , Jeffrey A. Sparks , Sarah P. Hammond , Zachary Wallace , Jatin M. Vyas , Amy K. Barczak , Jacob E. Lemieux , Jonathan Z. Li , and Mark J. Siedner Metrics Latest ePublished: 20 February 2024 Copyright & PermissionsCopyright © 2024 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...